As pioneers in wound irrigation, Irrimax has been integral in providing an alternative to traditional irrigation. With the introduction of its flagship, patented product, Irrisept®, in 2010, the company has seen widespread adoption in the US and internationally. Irrisept® is a solution comprising chlorhexidine gluconate (CHG) and sterile water for irrigation, suitable for various wound types and treatment stages. It is an improved alternative to saline and betadine because of CHG’s ability to act as a preservative and inhibit microbial growth to limit surgical site infections (SSIs). It is crucial in preventing the development of multidrug-resistant organisms (MDROs) and reducing the use of systemic antibiotics to treat infections, thus helping combat antimicrobial resistance (AMR).”